Crossref
Pembrolizumab in the non-small-cell lung cancer patients – reasons to consider its use
OncoReview · 2017
DOI: 10.24292/01.or.141217 ↗Kurz gefasst
Fachartikel in der Zeitschrift OncoReview, 2017. Verfasst von Magdalena Knetki-Wróblewska.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Knetki-Wróblewska, M. (2017). Pembrolizumab in the non-small-cell lung cancer patients – reasons to consider its use. OncoReview. https://doi.org/10.24292/01.or.141217
Vancouver
Knetki-Wróblewska M. Pembrolizumab in the non-small-cell lung cancer patients – reasons to consider its use. OncoReview. 2017. doi:10.24292/01.or.141217
BibTeX
@article{KnetkiWrblewska2017,
author = {Knetki-Wróblewska, Magdalena},
title = {Pembrolizumab in the non-small-cell lung cancer patients – reasons to consider its use},
journal = {OncoReview},
year = {2017},
doi = {10.24292/01.or.141217}
}
EUVIMED